Evaluation of immune-enhancing effects of ibuprofen in an immunodeficiency model. Academic Article uri icon

Overview

abstract

  • Three children and one adult with chronic mucocutaneous candidosis with documented deficient cellular immunity to Candida antigen were evaluated as a model to study the specific cellular immune-enhancing potential of the prostaglandin synthetase inhibitor ibuprofen. Oral ibuprofen failed to have any consistent effect during sequential 4-week on and off cycles on the following parameters: delayed hypersensitivity skin testing; lymphocyte transformation to Candida antigen; T-cell subsets as determined by monoclonal antibody techniques; production of human immune interferon in response to staphylococcal enterotoxin A (SEA). Two patients showed a trend toward enhanced lymphocyte transformation to PHA while taking ibuprofen. In two patients who were studied 8-10 weeks after discontinuation of oral ketoconazole therapy, clinical recurrence of CMC was not prevented by oral ibuprofen therapy.

publication date

  • April 1, 1985

Research

keywords

  • Candidiasis
  • Candidiasis, Chronic Mucocutaneous
  • Ibuprofen
  • Immunity, Cellular

Identity

Scopus Document Identifier

  • 0021920862

Digital Object Identifier (DOI)

  • 10.1111/j.1365-4362.1985.tb05755.x

PubMed ID

  • 3922905

Additional Document Info

volume

  • 24

issue

  • 3